In Silico Technologies: A Strategic Imperative for Accelerating Breakthroughs and Market Leadership for FDA-Regulated Products

This Reagan-Udall Foundation for the FDA report strives to bridge the gap between technical and business teams in the ecosystem of FDA-regulated products and the nation’s food supply by building the business case for industry investment in in silico technologies as a strategic imperative for accelerating breakthroughs and market leadership in FDA-regulated products, thus transforming human health.